A series of cardiometabolic-related items has been observed from Lilly, Metsera, Akero Therapeutics, Madrigal Pharmaceuticals, and Roche. Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic-related news items has been observed from Insulet, Senseonics, Zealand Pharma, Akero Therapeutics, Lilly, Skye Bioscience, and Biocon. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Zealand Pharma, FDA/OFA, Lilly, MannKind, Xeris, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic news items have been observed: Beta Bionics hosted its Q1 ‘25 earnings call (press release; slides); and MetaVia announced full results from its Ph2 DA-1241 study in MASH (press release; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
Novo Nordisk hosted its Q1 ’25 earnings call (press release; slides) and provided updates across its CVRM portfolio and Novo’s near-term obesity pipeline. Of note, Novo lowered its FY 2025 guidance due to reduced GLP-1RA market penetration as a result of compounding. Below, FENIX provides highlights and insights from the Q1 ’25 earnings call.
A series of cardiometabolic-related news items has been observed from Vertex Pharmaceuticals, Oura, Biomea Fusion, and Esperion. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Dexcom, Amgen, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly hosted its Q1 ’25 earnings call (press release; slides); Wegovy received preferred GLP-1RA status on CVS’s formulary (view press release); and Madrigal Pharmaceuticals hosted its Q1 ’25 earnings call (press release; slides). Below, FENIX provides highlights and insights from the respective news items.
A series of cardiometabolic-related news items has been observed from WeightWatchers, Creyon Bio, Tandem Diabetes Care, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Pfizer, Novartis, Regeneron Pharmaceuticals, Abbott, and Sequel Med Tech/Senseonics. Below, FENIX provides highlights and insights for the respective news items.